Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 12/20 | 0.65 |
| ▸ | APAF1 | O14727 | 6/20 | 0.65 |
| ▸ | CASP6 | P55212 | 5/20 | 0.65 |
| ▸ | TDP2 | O95551 | 4/20 | 0.65 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.65 |
| ▸ | SAE1 | Q9UBE0 | 4/20 | 0.59 |
| ▸ | UBA2 | Q9UBT2 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | THRB | P10828 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | UBE2I | P63279 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | BLM | P54132 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.59 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.59 |
| ▸ | AURKA | O14965 | 5/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3970835 | 0.83 | AURKA (0.56) | CDC25BAPAF1CASP6TDP2RCE1 | |
| SCHEMBL3968713 | 0.81 | CDC25B (0.50) | CDC25BAPAF1CASP6TDP2RCE1 | |
| SCHEMBL3971697 | 0.81 | CDC25B (0.50) | CDC25BAPAF1CASP6TDP2RCE1 | |
| SCHEMBL3969326 | 0.79 | AURKA (0.52) | CDC25BAPAF1CASP6TDP2RCE1 | |
| SCHEMBL3968830 | 0.78 | THRB (0.43) | CDC25BAPAF1CASP6TDP2RCE1 | |
| SCHEMBL3968427 | 0.78 | CDC25B (0.64) | CDC25BAPAF1CASP6TDP2RCE1 | |
| SCHEMBL3966868 | 0.75 | AURKA (0.50) | KDM4EALDH1A1AURKAAURKB | |
| SCHEMBL3972819 | 0.74 | AURKA (0.46) | CDC25BAPAF1CASP6TDP2RCE1 | |
| SCHEMBL3972635 | 0.74 | AURKA (0.46) | CDC25BAPAF1CASP6TDP2THRB | |
| SCHEMBL13912735 | 0.73 | AURKA (1.00) | AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572809-B2 | Isoquinoline aminopyrazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572809-B2 | Isoquinoline aminopyrazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7501495-B2 | Method for improving recovery yield in protein purification with gel filtration chromatography | AJINOMOTO CO., INC. (JP) | 2009-03-10 | — | — | US | disclosed |
| EP-1698637-B1 | A method for improving recovery yield in protein purification with gel filtration chromatography using arginine | AJINOMOTO KK (JP) | 2008-10-15 | — | — | EP | disclosed |
| EP-1966190-A1 | ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER | F.HOFFMANN-LA ROCHE AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| US-20070179151-A1 | Isoquinoline aminopyrazole derivatives | F. HOFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | US | disclosed |
| US-20070179151-A1 | Isoquinoline aminopyrazole derivatives | F. HOFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | US | disclosed |
| WO-2007071348-A1 | ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| US-20060199948-A1 | METHOD FOR IMPROVING RECOVERY YIELD IN PROTEIN PURIFICATION WITH GEL FILTRATION CHROMATOGRAPHY | AJINOMOTO CO., INC. (JP) | 2006-09-07 | — | — | US | disclosed |
| EP-1698637-A1 | A method for improving recovery yield in protein purification with gel filtration chromatography using arginine | AJINOMOTO CO., INC. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179151-A1 | Isoquinoline aminopyrazole derivatives | CYP3A5, CYP3A43, CYP3A4 | CDC25B 1925/4885APAF1 3366/4885CASP6 1754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.